Hountis Panagiotis, Matthaios Dimitrios, Froudarakis Marios, Bouros Demosthenes, Kakolyris Stylianos
Department of Thoracic Surgery, Athens Naval Hospital, Deinokratous 70, 11521, Athens, Greece,
Tumour Biol. 2014 Aug;35(8):7327-33. doi: 10.1007/s13277-014-2117-4. Epub 2014 May 27.
S100A2 is a member of the EF-hand motif family S100. Its role has been recently implicated in carcinogenesis and metastasis. Although its precise role in NSCLC patients is debated and conflicting results have been published, it has been associated with patient survival. S100A2 expression was downregulated in some studies while others disagree that S100A2 is strongly expressed in lung cancer. It has been recently published by Hountis et al. that there is a significant association between nuclear S100A2 positivity and better disease-free interval. Intensity of expression was the highest in the early and advanced stages, and equally distributed in the middle stages. This is indicative for a dual role of this protein in carcinogenesis. The expression of S100A2 in operable NSCLC varies widely, and this differential location and expression pattern (nuclear or cytoplasmic or both) seem to correlate with prognosis. The precise role for the movement of S100A2 protein between cytoplasm and nucleus is still unclear. We present here a literature review, and we propose the dual concept on its substantial role as a prognostic or predictive indicator in this unfavorable group of patients.
S100A2是EF手基序家族S100的成员之一。其作用最近被认为与致癌作用和转移有关。尽管其在非小细胞肺癌(NSCLC)患者中的精确作用存在争议,且已发表了相互矛盾的结果,但它与患者生存率相关。在一些研究中S100A2表达下调,而另一些研究则不同意S100A2在肺癌中高表达的观点。最近Hountis等人发表的研究表明,细胞核S100A2阳性与更好的无病生存期之间存在显著关联。表达强度在早期和晚期最高,在中期均匀分布。这表明该蛋白在致癌过程中具有双重作用。可手术的NSCLC中S100A2的表达差异很大,这种不同的定位和表达模式(细胞核或细胞质或两者皆有)似乎与预后相关。S100A2蛋白在细胞质和细胞核之间移动的确切作用仍不清楚。我们在此进行文献综述,并提出关于其在这类病情不利的患者群体中作为预后或预测指标的重要作用的双重概念。